Polydopamine as a biocompatible and precise mitochondrial targeted therapeutic platform for reversing myocardial ischemia-reperfusion injury.

ABSTRACT: Targeting mitochondria offers a compelling strategy for treating a broad spectrum of major diseases. However, the development of specific and biocompatible mitochondrial delivery vectors remains a key obstacle. In this study, we identified polydopamine (PDA)-a highly biocompatible material with inherent reactive oxygen species (ROS)-scavenging capabilities-as a naturally mitochondria-targeting biomaterial. PDA exhibits strong binding affinity to several critical outer mitochondrial membrane proteins, including the voltage-dependent anion channel and translocases of the outer membrane, conferring it with intrinsic mitochondrial tropism. As a proof-of-concept, we constructed a special channel PDA nanocapsule (CP) to encapsulate the mitochondrial permeability transition pore (mPTP) inhibitor

SUBMITTER: Zhao T 

PROVIDER: S-EPMC12528934 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature